|
시장보고서
상품코드
1935149
아토피 질환 치료제 시장 : 질환 유형별, 약제 클래스별, 투여 경로별, 최종사용자별, 유통 채널별, 환자 유형별, 지역별Atopic Disease Therapeutics Market, By Disease Type, By Drug Class, By Route of Administration, By End User, By Distribution Channel, By Patient Type, By Geography |
||||||
아토피 질환 치료제 시장은 2026년에 139억 달러로 추정되며, 2033년까지 262억 4,000만 달러에 이를 것으로 예측됩니다. 또한, 2026-2033년 CAGR 9.5%를 나타낼 전망입니다.
| 보고서의 내용 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 139억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 9.50% | 2033년 예측 가치 : | 262억 4,000만 달러 |
세계 아토피 질환 치료제 시장은 제약 및 생명공학 산업에서 중요한 부분을 차지하고 있으며, 면역 반응 증가와 피부 장벽 기능 장애를 특징으로 하는 일련의 만성 염증성 질환에 대응하고 있습니다. 아토피 피부염, 알레르기성 천식, 알레르기성 비염, 식품 알레르기를 포함한 아토피 질환은 전 세계 수백만 명에게 영향을 미치며, 의료비 부담을 가중시키고 환자의 삶의 질에 심각한 영향을 미치고 있습니다.
이러한 상호 연관된 질환들은 면역 반응의 조절 이상, 유전적 소인, 환경적 유발과 같은 공통된 병태생리학적 기전을 공유하며, 지속적인 염증과 조직 손상을 유발합니다. 아토피 질환의 치료 환경은 크게 진화하여 기존의 대증요법에서 표적 생물학적 제제 및 첨단 면역조절요법으로 전환되고 있습니다. 현대의 치료 접근법은 특히 인터루킨 신호전달 캐스케이드, IgE 매개 반응, Th2 세포 활성화 등 근본적인 염증 경로를 다루는 데 초점을 맞추었습니다.
시장에는 외용 코르티코스테로이드, 전신 면역억제제, 특정 사이토카인을 표적으로 하는 생물학적 제제, 저분자 억제제, 새로운 정밀의료 접근법 등 다양한 치료법이 있습니다. 아토피 질환의 유병률에 대한 인식 증가, 진단 능력의 향상, 효과적인 장기 관리 솔루션에 대한 환자 수요 증가는 시장 확대를 지속적으로 촉진하고 있으며, 이 분야는 상업적 잠재력이 큰 역동적이고 빠르게 진화하는 치료 영역으로 자리매김하고 있습니다.
시장 역학
세계 아토피 질환 치료제 시장은 주로 세계 아토피 질환의 유병률 증가에 의해 주도되고 있습니다. 특히 선진국에서는 환경적 요인, 생활양식의 변화, 진단 인식의 향상으로 질병에 대한 인식과 치료를 추구하는 행동이 증가하고 있습니다. 전 세계적으로 약 15-20%의 소아 및 1-3%의 성인에게 영향을 미치는 아토피 피부염 발병률 증가와 전 세계적으로 3억 건 이상의 알레르기성 천식 환자가 증가함에 따라 효과적인 치료법에 대한 시장 수요가 크게 증가하고 있습니다.
생물학적 제제 개발의 기술적 진보, 특히 IL-4, IL-13, IL-5, IgE 경로와 같은 특정 염증 매개체를 표적으로 하는 단일클론항체의 개발은 치료 패러다임에 혁명을 가져왔으며, 중등도에서 중증의 아토피 질환 환자들에게 치료 옵션을 넓혀주었습니다. 또한, 의료비 지출 증가, 전문 치료에 대한 보험 적용 범위 확대, 더 나은 삶의 질을 추구하는 환자 지원 활동의 활성화는 시장 성장을 더욱 촉진하고 있습니다. 그러나 시장에는 심각한 제약도 존재합니다. 신약 생물학적 제제 치료의 높은 비용(환자 1인당 연간 3만 달러가 넘는 경우도 적지 않음)은 접근 장벽을 만들어 가격에 민감한 시장에서의 보급을 제한하고 있습니다. 특히 소아 적응증에 대한 엄격한 의약품 승인 요건은 개발 기간의 장기화와 연구개발비용 증가를 초래하여 중소 제약사 시장 진입을 저해할 수 있습니다.
장기적인 면역억제제 사용에 따른 안전성 우려(감염 위험 증가, 잠재적 악성 종양 발생 우려 등)도 처방의사의 망설임과 환자의 복약 순응도 문제를 야기하고 있습니다. 그러나 헬스케어에 대한 인식이 높아지고 경제 상황이 개선되면서 첨단 치료법에 대한 수요가 증가하고 있는 신흥 시장에는 여전히 큰 기회가 존재합니다. 바이오마커 발굴, 유전자 프로파일링, 정밀 투약 전략을 활용한 개인 맞춤형 의료 접근법 개발은 큰 성장 잠재력을 가지고 있으며, 장벽 복구 메커니즘, 마이크로바이옴 조절, 혁신적인 약물 전달 시스템 등 새로운 치료 표적 탐색은 시장 확대와 차별화를 위한 유망한 경로를 제공합니다. 시장 확대와 차별화를 위한 유망한 경로를 제공합니다.
본 조사의 주요 특징
- 이 보고서는 아토피 질환 치료제 세계 시장에 대한 상세한 분석을 제공하며, 2025년을 기준 연도로 하여 예측 기간(2026-2033년) 시장 규모(10억 달러)와 연평균 성장률(CAGR)을 조사하여 전해드립니다.
- 또한, 각 부문의 잠재적 수익기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
- 시장 성장 촉진요인, 저해요인, 기회, 신제품 출시 또는 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략에 대한 중요한 정보를 제공합니다.
- 이 보고서는 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 전 세계 아토피 질환 치료제 시장의 주요 기업을 프로파일링합니다.
- 이 보고서는 각 기업의 마케팅 담당자와 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 이 세계 아토피 질환 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 아토피 질환 치료제 시장을 분석할 때 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 아토피 질환 치료제 시장 : 질환 유형별, 2021-2033년
제5장 세계의 아토피 질환 치료제 시장 : 약제 클래스별, 2021-2033년
제6장 세계의 아토피 질환 치료제 시장 : 투여 경로별, 2021-2033년
제7장 세계의 아토피 질환 치료제 시장 : 최종사용자별, 2021-2033년
제8장 세계의 아토피 질환 치료제 시장 : 유통 채널별, 2021-2033년
제9장 세계의 아토피 질환 치료제 시장 : 환자 유형별, 2021-2033년
제10장 세계의 아토피 질환 치료제 시장 : 지역별, 2021년-2033년
제11장 경쟁 구도
제12장 애널리스트 추천 사항
제13장 참고 문헌 및 조사 방법
LSH 26.03.09Atopic Disease Therapeutics Market is estimated to be valued at USD 13.9 Bn in 2026 and is expected to reach USD 26.24 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 13.9 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.50% | 2033 Value Projection: | USD 26.24 Bn |
The global atopic disease therapeutics market represents a critical segment within the pharmaceutical and biotechnology industries, addressing a spectrum of chronic inflammatory conditions characterized by heightened immune responses and skin barrier dysfunction. Atopic diseases, including atopic dermatitis, allergic asthma, allergic rhinitis, and food allergies, collectively affect millions of individuals worldwide, creating substantial healthcare burdens and significantly impacting patients' quality of life.
These interconnected conditions share common pathophysiological mechanisms involving dysregulated immune responses, genetic predisposition, and environmental triggers, leading to persistent inflammation and tissue damage. The therapeutic landscape for atopic diseases has evolved considerably, transitioning from traditional symptomatic treatments to targeted biologics and advanced immunomodulatory therapies. Modern treatment approaches focus on addressing underlying inflammatory pathways, particularly those involving interleukin signaling cascades, IgE-mediated responses, and Th2 cell activation.
The market encompasses various therapeutic modalities including topical corticosteroids, systemic immunosuppressants, biologics targeting specific cytokines, small molecule inhibitors, and emerging precision medicine approaches. Growing awareness of atopic disease prevalence, improved diagnostic capabilities, and increasing patient demand for effective long-term management solutions continue to drive market expansion, positioning this sector as a dynamic and rapidly evolving therapeutic area with significant commercial potential.
Market Dynamics
The global atopic disease therapeutics market is primarily driven by the escalating prevalence of atopic conditions worldwide, particularly in developed nations where environmental factors, lifestyle changes, and improved diagnostic awareness contribute to increased disease recognition and treatment seeking behavior. The rising incidence of atopic dermatitis, affecting approximately 15-20% of children and 1-3% of adults globally, coupled with growing allergic asthma rates exceeding 300 million cases worldwide, creates substantial market demand for effective therapeutic interventions.
Technological advancements in biologics development, particularly monoclonal antibodies targeting specific inflammatory mediators such as IL-4, IL-13, IL-5, and IgE pathways, have revolutionized treatment paradigms and expanded therapeutic options for patients with moderate-to-severe atopic diseases. Additionally, increased healthcare expenditure, improved insurance coverage for specialized treatments, and growing patient advocacy for better quality of life solutions further propel market growth. However, the market faces significant restraints including the high cost of novel biologic therapies, which often exceed $30,000 annually per patient, creating accessibility barriers and limiting adoption in price-sensitive markets. Stringent regulatory requirements for drug approval, particularly for pediatric indications, result in prolonged development timelines and increased R&D costs, potentially deterring smaller pharmaceutical companies from entering the market.
Safety concerns associated with long-term immunosuppressive therapy use, including increased infection risks and potential malignancy concerns, also create prescriber hesitancy and patient compliance challenges. Nevertheless, substantial opportunities exist in emerging markets where rising healthcare awareness and improving economic conditions drive demand for advanced therapeutics. The development of personalized medicine approaches utilizing biomarker identification, genetic profiling, and precision dosing strategies presents significant growth potential, while the exploration of novel therapeutic targets including barrier repair mechanisms, microbiome modulation, and innovative drug delivery systems offers promising avenues for market expansion and differentiation.
Key Features of the Study
- This report provides in-depth analysis of the global atopic disease therapeutics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global atopic disease therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc, Sanofi, AbbVie Inc, Galderma Laboratories, L.P., Eli Lilly and Company, Regeneron Pharmaceuticals Inc, LEO Pharma Inc, Otsuka Pharmaceutical Co., Ltd, Novartis AG, Incyte Corporation, Astellas Pharma Inc, Bayer AG, Allergan plc, Amgen Inc, and GlaxoSmithKline plc
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global atopic disease therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global atopic disease therapeutics market
Market Segmentation
- Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
- Atopic Dermatitis
- Allergic Rhinitis
- Asthma
- Food Allergies
- Conjunctivitis
- Others
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Topical Steroids
- Topical Calcineurin Inhibitors
- Biologics (e.g., Monoclonal Antibodies, JAK Inhibitors)
- Systemic Steroids
- Immunosuppressants
- Others
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Topical
- Oral
- Injectable
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Dermatology Clinics
- Homecare Settings
- Pharmacies
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Online
- Offline
- Patient Type Insights (Revenue, USD Bn, 2021 - 2033)
- Acute
- Chronic
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc
- Sanofi
- AbbVie Inc
- Galderma Laboratories, L.P.
- Eli Lilly and Company
- Regeneron Pharmaceuticals Inc
- LEO Pharma Inc
- Otsuka Pharmaceutical Co., Ltd
- Novartis AG
- Incyte Corporation
- Astellas Pharma Inc
- Bayer AG
- Allergan plc
- Amgen Inc
- GlaxoSmithKline plc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Atopic Disease Therapeutics Market, By Disease Type
- Global Atopic Disease Therapeutics Market, By Drug Class
- Global Atopic Disease Therapeutics Market, By Route of Administration
- Global Atopic Disease Therapeutics Market, By End User
- Global Atopic Disease Therapeutics Market, By Distribution Channel
- Global Atopic Disease Therapeutics Market, By Patient Type
- Global Atopic Disease Therapeutics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Atopic Disease Therapeutics Market, By Disease Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Atopic Dermatitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Allergic Rhinitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Food Allergies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Conjunctivitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Atopic Disease Therapeutics Market, By Drug Class, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Topical Steroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Topical Calcineurin Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Biologics (e.g., Monoclonal Antibodies, JAK Inhibitors)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Systemic Steroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Immunosuppressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Atopic Disease Therapeutics Market, By Route of Administration, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Atopic Disease Therapeutics Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Dermatology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global Atopic Disease Therapeutics Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Online
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Offline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
9. Global Atopic Disease Therapeutics Market, By Patient Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Acute
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Chronic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
10. Global Atopic Disease Therapeutics Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Galderma Laboratories, L.P.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- LEO Pharma Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Incyte Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergan plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
